NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, News, & Analysis

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its earnings results on Thursday, August, 9th. The biotechnology company reported $0.00 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.01 by $0.01. The biotechnology company had revenue of $11.69 million for the quarter, compared to the consensus estimate of $13.46 million. Pieris Pharmaceuticals had a negative return on equity of 27.81% and a negative net margin of 22.38%. View Pieris Pharmaceuticals' Earnings History.

Pieris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Pieris Pharmaceuticals.

5 brokers have issued 12 month target prices for Pieris Pharmaceuticals' stock. Their predictions range from $12.00 to $13.00. On average, they anticipate Pieris Pharmaceuticals' stock price to reach $12.3333 in the next twelve months. This suggests a possible upside of 135.4% from the stock's current price. View Analyst Price Targets for Pieris Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pieris Pharmaceuticals.

Some companies that are related to Pieris Pharmaceuticals include National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), VIRALYTICS Ltd/S (VRACY), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Dyadic International, Inc common stock (DYAI), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), Protalex (PRTX) and US Stem Cell (USRM).

Headlines about PIRS stock have been trending somewhat positive on Tuesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a news impact score of 0.15 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 48.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Pieris Pharmaceuticals.

Pieris Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (5.81%), BlackRock Inc. (4.97%), Acadian Asset Management LLC (3.94%), Aquilo Capital Management LLC (3.66%), Prosight Management LP (2.52%) and Millennium Management LLC (2.00%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, James A Geraghty and Orbimed Advisors Llc. View Institutional Ownership Trends for Pieris Pharmaceuticals.

PIRS stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, Bank of New York Mellon Corp, Trexquant Investment LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

PIRS stock was acquired by a variety of institutional investors in the last quarter, including Aquilo Capital Management LLC, BlackRock Inc., Prosight Management LP, Acadian Asset Management LLC, American Century Companies Inc., GSA Capital Partners LLP, Spark Investment Management LLC and Assenagon Asset Management S.A.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine and James A Geraghty. View Insider Buying and Selling for Pieris Pharmaceuticals.

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PIRS stock can currently be purchased for approximately $5.24.

Pieris Pharmaceuticals has a market capitalization of $275.04 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]